C2C_ASC110

DRUG2 trials

Sponsors

Cell2Cure ApS, Cell to Cure ApS

Conditions

Autism spectrum disorderGastrointestinal symptomsNon-ischemic heart failure with reduced ejection fraction

Phase 1

An open label safety and efficacy study of allogenic adipose tissue-derived mesenchymal stromal cells on autism and gastrointestinal symptoms

WithdrawnCTIS2025-523699-21-00

Cell to Cure ApSAutism spectrum disorder, Gastrointestinal symptoms

Target: 40Updated: 2026-01-23

Phase 2

A Danish, double-blind, randomized placebo-controlled clinical trial evaluating allogeneic adipose tissue derived mesenchymal stromal cell therapy in patients with recently diagnosed non-ischemic heart failure with reduced ejection fraction.

Not yet recruitingCTIS2025-520837-22-00

Cell2Cure ApSNon-ischemic heart failure with reduced ejection fraction

Target: 90Updated: 2025-12-08

Related Papers

Adipose tissue-derived mesenchymal stromal cell therapy in nonischemic heart failure with reduced ejection fraction - ARIISE study design.

2026-03-25